Keyphrases
Metastatic Breast Cancer
100%
Tissue Inhibitor of metalloproteinase-1 (TIMP-1)
100%
Plasma Tissue
100%
Overall Survival
25%
Plasma Parameters
16%
Hormone Therapy
16%
Time to Progression
16%
Growth Factors
8%
Multivariate Analysis
8%
Enzyme-linked Immunosorbent Assay (ELISA)
8%
Catalytic Activity
8%
Univariate Analysis
8%
Prognostic Factors
8%
Reduced Survival
8%
Human Epidermal Growth Factor Receptor 2 (HER2)
8%
Mean Standard Deviation
8%
Ethylenediamine
8%
Upper Normal Limit
8%
Matrix Metalloproteinases
8%
Healthy Postmenopausal Women
8%
Clinical Benefit Rate
8%
Medicine and Dentistry
Metastatic Breast Cancer
100%
Tissue Inhibitor of Metalloproteinase 1
100%
Overall Survival
27%
Hormone Therapy
18%
Multivariate Analysis
9%
Univariate Analysis
9%
Growth Factor
9%
Postmenopause
9%
Prognostic Factor
9%
Enzyme Linked Immunosorbent Assay
9%
Matrix Metalloproteinase
9%
Metalloprotease Inhibitor
9%
Visceral Metastasis
9%
Ethylenediamine
9%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Breast Cancer
100%
Tissue Inhibitor of Metalloproteinase 1
100%
Overall Survival
27%
Endocrine Therapy
18%
Enzyme-Linked Immunosorbent Assay
9%
Growth Factor
9%
Matrix Metalloproteinase
9%
Ethylenediamine
9%
Biochemistry, Genetics and Molecular Biology
Metalloprotease Inhibitor
100%
Overall Survival
25%
Blood Level
16%
Postmenopause
8%
Growth Factor
8%
Enzyme
8%
Multivariate Analysis
8%
Matrix Metalloproteinase
8%
Neuroscience
Metalloprotease Inhibitor
100%
Hormone Therapy
16%
Growth Factor
8%
Matrix Metalloproteinase
8%